USE OF 177Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
Open Access
- 29 June 2021
- journal article
- review article
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 20 (3) , 115-123
Abstract
Purpose of the study: to present current data regarding challenges in treatment of castration-resistant prostate cancer (CRPC) and the relationship between CRPC and the expression of prostate-specific membrane antigen (psma).Material and Methods. The search for relevant sources was carried out in the Pubmed, elibrary, Medline databases. The review included 43 publications, most of which were published over the past 5 years.Results. Currently, prostate cancer (PC) is one of the most common cancers in men. Moreover, over time, most patients develop resistance to therapy, which significantly worsens the prognosis of the disease. Psma is one of the molecular markers of prostate cancer; a number of studies have demonstrated a direct correlation between the level of psma expression and the tumor grade, stage and aggressiveness. Numerous studies indicate that psma represents an excellent target for radionuclide therapy of prostate cancer. 68Ga or 18F-psma Pet/Ct is the most common method for diagnosing PC. It should be noted that modern trends in the development of nuclear medicine are closely related to theranostics; therefore, the creation of highly specific theranostic pairs for diagnosis and subsequent therapy of malignant tumors is of great significance. The data obtained indicate that 177lu demonstrates the most optimal radiation and physical characteristics for therapeutic radionuclides, while psma-617 is one of the most studied ligands for radionuclide therapy.Conclusion. Currently, there are several studies covering radionuclide therapy with various psmacompounds labeled with 177lu. Radionuclide therapy with 177lu-psma has been shown to be recommended for patients with metastatic CRPC, who have no benefits from alternative therapies or have contraindications to them.Keywords
This publication has 37 references indexed in Scilit:
- The National Registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian FederationCancer Urology, 2019
- Second line chemotherapy in patients with castration-refractory prostate cancer. Ftom clinical studies to practiceCancer Urology, 2019
- SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIESCancer Urology, 2018
- Metastatic castration-resistant prostate cancer: a current view on drug therapy and alternative tumor cell regulationCancer Urology, 2018
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2016
- Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancerOncotarget, 2016
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate CancerJournal of Nuclear Medicine, 2015
- Visceral Disease in Castration-resistant Prostate CancerEuropean Urology, 2014
- Treatment Patterns in Patients With Prostate Cancer and Bone Metastasis Among US Community-based Urology Group PracticesUrology, 2012
- Predictive modelling in hormone-refractory prostate cancer (HRPC).Clinical and Translational Oncology, 2009